Thelansis’s "Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder caused by pathogenic DMD variants that reduce or eliminate dystrophin, a protein that stabilizes muscle fibers. It mainly affects boys and leads to progressive weakness, difficulty walking, loss of ambulation, and later cardiac or respiratory complications. Care includes corticosteroids or vamorolone, rehabilitation, and cardiac and respiratory monitoring. Givinostat is approved in the United States for patients aged 6 years and older; exon-skipping drugs apply only to specific mutations, and clinical benefits vary. Elevidys gene therapy is approved for ambulatory patients aged 4 years and older with a confirmed DMD mutation, but carries a boxed warning for acute serious liver injury and liver failure. These treatments may slow aspects of disease but do not cure DMD. Research continues on better genetic approaches and therapies that preserve muscle and cardiopulmonary function.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Duchenne Muscular Dystrophy (DMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Duchenne Muscular Dystrophy (DMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.